Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

In an open-label, randomized, noninferiority trial, dolutegravir-based antiretroviral therapy was compared with standard care in children and adolescents starting first- or second-line therapy for HIV type 1 infection. Dolutegravir-based ART was superior to standard-care ART.

Uložené v:

Podrobná bibliografia
Vydané v:	The New England journal of medicine Ročník 385; číslo 27; s. 2531 - 2543
Hlavní autori:	Turkova, Anna, White, Ellen, Mujuru, Hilda A, Kekitiinwa, Adeodata R, Kityo, Cissy M, Violari, Avy, Lugemwa, Abbas, Cressey, Tim R, Musoke, Philippa, Variava, Ebrahim, Cotton, Mark F, Archary, Moherndran, Puthanakit, Thanyawee, Behuhuma, Osee, Kobbe, Robin, Welch, Steven B, Bwakura-Dangarembizi, Mutsa, Amuge, Pauline, Kaudha, Elizabeth, Barlow-Mosha, Linda, Makumbi, Shafic, Ramsagar, Nastassja, Ngampiyaskul, Chaiwat, Musoro, Godfrey, Atwine, Lorna, Liberty, Afaaf, Musiime, Victor, Bbuye, Dickson, Ahimbisibwe, Grace M, Chalermpantmetagul, Suwalai, Ali, Shabinah, Sarfati, Tatiana, Wynne, Ben, Shakeshaft, Clare, Colbers, Angela, Klein, Nigel, Bernays, Sarah, Saïdi, Yacine, Coelho, Alexandra, Grossele, Tiziana, Compagnucci, Alexandra, Giaquinto, Carlo, Rojo, Pablo, Ford, Deborah, Gibb, Diana M
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Massachusetts Medical Society 30.12.2021
Predmet:	Acquired immune deficiency syndrome Administration, Oral Adolescence Adolescent Adolescents Adverse events AIDS Alkynes - therapeutic use Anti-Retroviral Agents - adverse effects Anti-Retroviral Agents - therapeutic use Antiretroviral drugs Antiretroviral therapy Benzoxazines - therapeutic use Caregivers Child Child, Preschool Children Cholesterol - blood Cyclopropanes - therapeutic use Drug Therapy, Combination Efavirenz FDA approval Female Global Health Heterocyclic Compounds, 3-Ring - administration & dosage Heterocyclic Compounds, 3-Ring - adverse effects Heterocyclic Compounds, 3-Ring - therapeutic use HIV HIV Infections - drug therapy HIV Infections - virology HIV Integrase Inhibitors - administration & dosage HIV Integrase Inhibitors - adverse effects HIV Integrase Inhibitors - therapeutic use HIV Protease Inhibitors - therapeutic use HIV-1 - isolation & purification Human immunodeficiency virus Humans Immune system Infections Infectious Disease Integrase Life Sciences Male Mutation Oxazines - administration & dosage Oxazines - adverse effects Oxazines - therapeutic use Pediatrics Pediatrics General Piperazines - administration & dosage Piperazines - adverse effects Piperazines - therapeutic use Proteinase inhibitors Pyridones - administration & dosage Pyridones - adverse effects Pyridones - therapeutic use Santé publique et épidémiologie Teenagers Viral Load - drug effects
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	In an open-label, randomized, noninferiority trial, dolutegravir-based antiretroviral therapy was compared with standard care in children and adolescents starting first- or second-line therapy for HIV type 1 infection. Dolutegravir-based ART was superior to standard-care ART.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 PMCID: PMC7614690 The members of the ODYSSEY Trial Team are listed in the Supplementary Appendix, available at NEJM.org.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2108793